Fosphenytoin
Epilepsy With Generalized Tonic-Clonic Seizures
Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Emory University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00510783CT.gov IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epilepsy With Generalized Tonic-Clonic Seizures
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fosphenytoin (this asset) | Emory University | Approved | B · 61 |
| Lamotrigine | GlaxoSmithKline | P4 | BBB |
| Midazolam | Pakistan Air Force (PAF) Hospital Islamabad | P4 | BB |
| Levetiracetam | Emory University | P4 | BB |
| Topiramate | GlaxoSmithKline | P3 | BB |
| Pregabalin | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | P3 | BB |
| Zonisamide | Affiliated Hospital of Nantong University | P4 | B |
| Phenytoin | Emory University | P4 | B |
| Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- | Zogenix, Inc. | P3 | B |
+4 more in the Epilepsy With Generalized Tonic-Clonic Seizures cohort
Other indications for Fosphenytoin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Traumatic Brain Injury | — | P4 | B · 58 |
| Brain Ischemia | — | P4 | B · 58 |
| Brain Hypoxia - Ischemia | — | P4 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Fosphenytoin in Epilepsy With Generalized Tonic-Clonic Seizures. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/fosphenytoin-epilepsy-with-generalized-tonic-clonic-seizures
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →